Download PDF
CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2018; 27(03): 203-213
DOI: 10.1055/s-0038-1676044
SCU Guidelines | Guias Clinicas SCU
Sociedad Colombiana de Urología. Publicado por Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Resumen de la Guía de Práctica Clínica de Disfunción Eréctil – Sociedad Colombiana de Urología

Clinical Practice Guideline for Erectile Dysfunction – Colombian Society of Urology
María del Pilar Ceballos
1   Urólogo, Medicina Sexual, Bogotá, Bogotá, Colombia
,
Juan Fernando Uribe Arcila
2   Urólogo, Medicina Sexual, PAR EXTERNO REVISOR DE GUIA, Sociedad Latinoamericana de Medicina Sexual – SLAMS, Sociedad de Medicina Sexual de Norte América – SMSNA, Vicepresidente de la SCU, Bogotá, Colombia
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2018 (online)

   Permissions and Reprints

Métodos

Se realizó el análisis de las guías más importantes en el tema de disfunción eréctil incluyendo las de la Sociedad Europea de Urología (EAU) 2017, Sociedad Americana de Urología (AUA) 2018, Sociedad Británica de Urología 2018 y la Sociedad Japonesa de Urología (de las cuales fueron adaptadas las guías iniciales 2014), publicadas hasta Agosto del 2018.

La adaptación inicial de esas guías fue realizada empleando la metodología del NZGG, que incluyó la revisión sistemática de la literatura y guías disponibles hasta Diciembre de 2012 con un análisis crítico utilizando la herramienta AGREE II.

Se solicitó autorización a los autores para la adaptación y aplicación de la guía seleccionada por parte del comité evaluador.

Adicionalmente se llevó a cabo una búsqueda utilizando el motor FABUMED (Un metabuscador), basado en las estrategias de búsqueda de Mac Máster University, con la capacidad de seleccionar ensayos clínicos y revisiones sistemáticas con alta sensibilidad y especificidad, el cual complementó el contenido de esta guía.

 

  • Bibliografía

  • 1 McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 04) S6-S11
    CrossrefPubMedGoogle Scholar
  • 2 Lue T, Basson R, Rosen R, Guiliano F, Khoury S. Sexual Medicine: Sexual Dysfunctions in men and Women. Paris: Health Prod; 2004
    Google Scholar
  • 3 Morillo LE, Díaz J, Estevez E. , et al. Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: a population-based study (DENSA). Int J Impot Res 2002; 14 (Suppl. 02) S10-S18
    CrossrefPubMedGoogle Scholar
  • 4 Acuña Cañas A, Ceballos Domínguez MP, López Ramos H, Suárez PA. Investigación Original Síndrome metabólico y disfunción eréctil en la población colombiana Urol.colomb. Vol XX, No. 3: pp. 55–60, 2011
    Google Scholar
  • 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Erectile Disorder DSM-5 302.72 (F52.21) Arlington, VA: American Psychiatric Publishing ; 2013
    Google Scholar
  • 6 McCabe MP, Sharlip ID, Atalla E. , et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016; 13 (02) 135-143
    CrossrefPubMedGoogle Scholar
  • 7 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151 (01) 54-61
    CrossrefPubMedGoogle Scholar
  • 8 Feldman HA, Johannes CB, Derby CA. , et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30 (04) 328-338
    CrossrefPubMedGoogle Scholar
  • 9 Tengs TO, Osgood ND. The link between smoking and impotence: two decades of evidence. Prev Med 2001; 32 (06) 447-452
    CrossrefPubMedGoogle Scholar
  • 10 Hirshkowitz M, Karacan I, Howell JW, Arcasoy MO, Williams RL. Nocturnal penile tumescence in cigarette smokers with erectile dysfunction. Urology 1992; 39 (02) 101-107
    CrossrefPubMedGoogle Scholar
  • 11 Allen MS, Walter EE. Health-Related Lifestyle Factors and Sexual Dysfunction: A Meta-Analysis of Population-Based Research. J Sex Med 2018; 15 (4): 458-475
    CrossrefPubMedGoogle Scholar
  • 12 Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J Urol 2005; 174 (01) 244-248
    CrossrefPubMedGoogle Scholar
  • 13 Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens 2008; 26 (11) 2074-2084
    CrossrefPubMedGoogle Scholar
  • 14 Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep 2012; 14 (04) 285-292
    CrossrefPubMedGoogle Scholar
  • 15 Weinhardt LS, Carey MP. Prevalence of erectile disorder among men with diabetes mellitus: comprehensive review, methodological critique and suggestions for future research. J Sex Res 1996; 33: 205-214
    CrossrefPubMedGoogle Scholar
  • 16 Gazzaruso C, Giordanetti S, De Amici E. , et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110 (01) 22-26
    CrossrefPubMedGoogle Scholar
  • 17 Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25 (08) 1458-1463
    CrossrefPubMedGoogle Scholar
  • 18 Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171 (6 Pt 1): 2341-2345
    CrossrefPubMedGoogle Scholar
  • 19 Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140 (10) 930-937
    CrossrefPubMedGoogle Scholar
  • 20 Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172 (01) 255-258
    CrossrefPubMedGoogle Scholar
  • 21 Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19 (01) 95-98
    CrossrefPubMedGoogle Scholar
  • 22 Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. ; Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166 (02) 207-212
    CrossrefPubMedGoogle Scholar
  • 23 Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?. Urology 2000; 56 (02) 302-306
    CrossrefPubMedGoogle Scholar
  • 24 Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171 (20) 1797-1803
    CrossrefPubMedGoogle Scholar
  • 25 Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139 (03) 161-168
    PubMedGoogle Scholar
  • 26 Pohjantähti-Maaroos H, Palomäki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovasc Disord 2011; 11: 36
    CrossrefPubMedGoogle Scholar
  • 27 Montorsi P, Ravagnani PM, Galli S. , et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006; 27 (22) 2632-2639
    CrossrefPubMedGoogle Scholar
  • 28 Miner MM. Erectile dysfunction and the “window of curability”: a harbinger of cardiovascular events. Mayo Clin Proc 2009; 84 (02) 102-104
    CrossrefPubMedGoogle Scholar
  • 29 Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294 (23) 2996-3002
    CrossrefPubMedGoogle Scholar
  • 30 Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998; 60 (04) 458-465
    CrossrefPubMedGoogle Scholar
  • 31 Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl. 01) 26-33
    CrossrefPubMedGoogle Scholar
  • 32 van Moorselaar RJA, Hartung R, Emberton M. , et al; ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95 (04) 603-608
    CrossrefPubMedGoogle Scholar
  • 33 Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324 (7345): 1059-1061
    CrossrefPubMedGoogle Scholar
  • 34 Gonzalez RR, Kaplan SA. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2006; 2 (04) 609-617
    CrossrefPubMedGoogle Scholar
  • 35 Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med 2009; 6 (08) 2299-2304
    CrossrefPubMedGoogle Scholar
  • 36 Rosen R, Altwein J, Boyle P. , et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (06) 637-649
    CrossrefPubMedGoogle Scholar
  • 37 Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med 2013; 10 (02) 551-561
    CrossrefPubMedGoogle Scholar
  • 38 Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34 (04) 327-331
    CrossrefPubMedGoogle Scholar
  • 39 Nehra A, Jackson G, Miner M. , et al. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol 2013; 189 (06) 2031-2038
    CrossrefPubMedGoogle Scholar
  • 40 Böhm M, Baumhäkel M, Teo K. , et al; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121 (12) 1439-1446
    CrossrefPubMedGoogle Scholar
  • 41 Montorsi EC. 2006 Londoño (Miner Mayo Clinic Proc- 2009). Thompson: JAMA; 2005
    Google Scholar
  • 42 Nehra A, Jackson G, Miner M. , et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (08) 766-778
    CrossrefPubMedGoogle Scholar
  • 43 DeBusk R, Drory Y, Goldstein I. , et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 2000; 86 (02) 175-181
    CrossrefPubMedGoogle Scholar
  • 44 Levine GN, Steinke EE, Bakaeen FG. , et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125 (08) 1058-1072
    CrossrefPubMedGoogle Scholar
  • 45 Wang C, Nieschlag E, Swerdloff R. , et al; International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30 (01) 1-9
    PubMedGoogle Scholar
  • 46 Wu FC, Tajar A, Beynon JM. , et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363 (02) 123-135
    CrossrefPubMedGoogle Scholar
  • 47 Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60 (07) 762-769
    PubMedGoogle Scholar
  • 48 Vignozzi L, Morelli A, Filippi S. , et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007; 4 (03) 620-632
    CrossrefPubMedGoogle Scholar
  • 49 Morelli A, Filippi S, Mancina R. , et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145 (05) 2253-2263
    CrossrefPubMedGoogle Scholar
  • 50 Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7 (01) 46-56
    CrossrefPubMedGoogle Scholar
  • 51 Hamidi Madani A, Heidarzadeh A, Akbari Parsa N, Khosravi Darestani F, Hamidi Madani Z. A survey on relative frequency of metabolic syndrome and testosterone deficiency in men with erectile dysfunction. Int Urol Nephrol 2012; 44 (03) 667-672
    CrossrefPubMedGoogle Scholar
  • 52 Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007; 100 (03) 509-513
    CrossrefPubMedGoogle Scholar
  • 53 Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58 (06) 710-717
    CrossrefPubMedGoogle Scholar
  • 54 Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. , The Laboratory Diagnosis of Testosterone Deficiency. White Paper. 2013 American Urological Association Education and Research, Inc.
    PubMedGoogle Scholar
  • 55 Hellstrom WJ, Paduch D, Donatucci CF. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. Int Urol Nephrol 2012; 44 (01) 61-70
    CrossrefPubMedGoogle Scholar
  • 56 de Ronde W, van der Schouw YT, Pols HAP. , et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem 2006; 52 (09) 1777-1784
    CrossrefPubMedGoogle Scholar
  • 57 Knoblovits P, Costanzo PR, Valzacchi GJ. , et al. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl 2010; 31 (03) 263-270
    CrossrefPubMedGoogle Scholar
  • 58 Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Maggi M. Testosterone and cardiovascular risk in patients with erectile dysfunction. J Endocrinol Invest 2012; 35 (09) 809-816
    PubMedGoogle Scholar
  • 59 Testosterone Prescriptions Plunge After CVD. Signals, FDA Alert – Medscape. Marlene Busko; 2018
    Google Scholar
  • 60 Lin JW, Lee JK, Wu CK. , et al. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011; 8 (08) 2350-2360
    CrossrefPubMedGoogle Scholar
  • 61 García-Cruz E, Leibar-Tamayo A, Romero J. , et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med 2013; 10 (10) 2529-2538
    CrossrefPubMedGoogle Scholar
  • 62 Laaksonen DE, Niskanen L, Punnonen K. , et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149 (06) 601-608
    CrossrefPubMedGoogle Scholar
  • 63 Laaksonen DE, Niskanen L, Punnonen K. , et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90 (02) 712-719
    CrossrefPubMedGoogle Scholar
  • 64 Corona G, Monami M, Rastrelli G. , et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8 (01) 272-283
    CrossrefPubMedGoogle Scholar
  • 65 Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. Am J Med 2017; 130 (03) 293-305
    CrossrefPubMedGoogle Scholar
  • 66 Guay AT, Traish A. Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am 2011; 38 (02) 175-183
    CrossrefPubMedGoogle Scholar
  • 67 Nieschlag E, Swerdloff R, Behre HM. , et al; International Society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU). Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48 (01) 1-4
    CrossrefPubMedGoogle Scholar
  • 68 Bhasin S, Cunningham GR, Hayes FJ. , et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91 (06) 1995-2010
    CrossrefPubMedGoogle Scholar
  • 69 Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K. ; British Society for Sexual Medicine. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction. J Sex Med 2008; 5 (08) 1841-1865
    CrossrefPubMedGoogle Scholar
  • 70 Carani C, Isidori AM, Granata A. , et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90 (12) 6472-6479
    CrossrefPubMedGoogle Scholar
  • 71 Vigen R, O'Donnell CI, Barón AE. , et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310 (17) 1829-1836
    CrossrefPubMedGoogle Scholar
  • 72 Finkle WD, Greenland S, Ridgeway GK. , et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9 (01) e85805 Doi: 10.1371/journal.pone.0085805
    CrossrefPubMedGoogle Scholar
  • 73 http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf
    PubMed
  • 74 Burnett AL, Nehra A, Breau RH. , et al. American Urological Association (AUA) ERECTILE DYSFUNCTION: AUA GUIDELINE. American Urological Association Education and Research, Inc; 2018
    Google Scholar
  • 75 McDougal W, Wein A, Kavoussi L. , et al. Campbell-Walsh Urology. 10th Edition. SECTION XVI q Prostate. Chapter 93–94. Saunders: Philadelphia; 2012
    Google Scholar
  • 76 Peltier A, van Velthoven R, Roumeguère T. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol 2009; 21 (04) 303-309
    CrossrefPubMedGoogle Scholar
  • 77 Hatzimouratidis K. (Chair), Giuliano F, Moncada I, Muneer A, Salonia A. (Vice-chair), Verze P. EUA Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism. European Association of Urology; 2016
    Google Scholar
  • 78 J Endocrinology. Krasas Mayo 2008. J. Endocrology 2005- Carani Cesar Diciembre 2005
    PubMedGoogle Scholar
  • 79 Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013; 10 (01) 120-129
    PubMedGoogle Scholar
  • 80 Trombetta C, Mazzon G, Liguori G. , et al. Clinical Evaluation of Erectile Dysfunction in the Era of PDE-5 Inhibitors: The Residual Role of Penile Color Doppler US (Chapter IV). In: Bertolotto M, Trombetta C. (editors). Scrotal Pathology (Medical Radiology/Diagnostic Imaging). Springer: Berlin; 2008: 22
    Google Scholar
  • 81 Schwartz AN, Lowe M, Berger RE, Wang KY, Mack LA, Richardson ML. Assessment of normal and abnormal erectile function: color Doppler flow sonography versus conventional techniques. Radiology 1991; 180 (01) 105-109
    CrossrefPubMedGoogle Scholar
  • 82 Bertolotto M, Lissiani A, Pizzolato R, Fute MD. Common Findings and Anatomical Variations. (Chapter V). In: Bertolotto M, Trombetta C. (editors). Scrotal Pathology (Medical Radiology / Diagnostic Imaging). Springer: Berlin; 2008: 42-28
    Google Scholar
  • 83 Broderick GA, Arger P. Duplex Doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol 1993; 28 (01) 43-56
    CrossrefPubMedGoogle Scholar
  • 84 Lee B, Sikka SC, Randrup ER. , et al. Standardization of penile blood flow parameters in normal men using intracavernous prostaglandin E1 and visual sexual stimulation. J Urol 1993; 149 (01) 49-52
    CrossrefPubMedGoogle Scholar
  • 85 Montorsi F, Sarteschi M, Maga T. , et al. Functional anatomy of cavernous helicine arterioles in potent subjects. J Urol 1998; 159 (03) 808-810
    CrossrefPubMedGoogle Scholar
  • 86 Bertolotto M, Neumaier CE, Martinoli C, Quaia E, Savoca G. Color Doppler appearance of penile cavernosal-spongiosal communications in patients with normal and impaired erection. Eur Radiol 2002; 12 (09) 2287-2293
    CrossrefPubMedGoogle Scholar
  • 87 Mancini M, Bartolini M, Maggi M, Innocenti P, Villari N, Forti G. Duplex ultrasound evaluation of cavernosal peak systolic velocity and waveform acceleration in the penile flaccid state: clinical significance in the assessment of the arterial supply in patients with erectile dysfunction. Int J Androl 2000; 23 (04) 199-204
    CrossrefPubMedGoogle Scholar
  • 88 Aversa A, Sarteschi LM. The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction. J Sex Med 2007; 4 (05) 1437-1447
    CrossrefPubMedGoogle Scholar
  • 89 Valji K, Bookstein JJ. Diagnosis of arteriogenic impotence: efficacy of duplex sonography as a screening tool. AJR Am J Roentgenol 1993; 160 (01) 65-69
    CrossrefPubMedGoogle Scholar
  • 90 Ga B. Color dúplex Doppler ultrasound: penile blood flow study.Male infertility and sexual dysfunction Ed. WJG Hellstrom New York: Inc; 1997: 367-395
    Google Scholar
  • 91 Golijanin D, Singer E, Davis R, Bhatt S, Seftel A, Dogra V. Doppler evaluation of erectile dysfunction - part 1. Int J Impot Res 2007; 19 (01) 37-42
    CrossrefPubMedGoogle Scholar
  • 92 Golijanin D, Singer E, Davis R, Bhatt S, Seftel A, Dogra V. Doppler evaluation of erectile dysfunction - part 2. Int J Impot Res 2007; 19 (01) 43-48
    CrossrefPubMedGoogle Scholar
  • 93 Halls J, Bydawell G, Patel U. Erectile dysfunction: the role of penile Doppler ultrasound in diagnosis. Abdom Imaging 2009; 34 (06) 712-725
    CrossrefPubMedGoogle Scholar
  • 94 Kim ED, Blackburn D, McVary KT. Post-radical prostatectomy penile blood flow: assessment with color flow Doppler ultrasound. J Urol 1994; 152 (6 Pt 2): 2276-2279
    CrossrefPubMedGoogle Scholar
  • 95 Wespes E, Raviv G, Vanegas JP. , et al. Corporeal veno-occlusive dysfunction: a distal arterial pathology?. J Urol 1998; 160 (6 Pt 1): 2054-2057
    CrossrefPubMedGoogle Scholar
  • 96 de Meyer JM, Thibo P. The correlation among cavernous pressure, penile rigidity and resistance index. J Urol 1998; 160 (01) 63-66
    CrossrefPubMedGoogle Scholar
  • 97 Sanda MG, Dunn RL, Michalski J. , et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358 (12) 1250-1261
    CrossrefPubMedGoogle Scholar
  • 98 Ficarra V, Novara G, Ahlering TE. , et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 62 (03) 418-430
    CrossrefPubMedGoogle Scholar
  • 99 Moskovic DJ, Miles BJ, Lipshultz LI, Khera M. Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. Int J Impot Res 2011; 23 (05) 181-192
    CrossrefPubMedGoogle Scholar
  • 100 Hyun JS. Prostate cancer and sexual function. World J Mens Health 2012; 30 (02) 99-107
    CrossrefPubMedGoogle Scholar
  • 101 Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008; 18 (06) 613-620
    CrossrefPubMedGoogle Scholar
  • 102 Salonia A, Burnett AL, Graefen M. , et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62 (02) 261-272
    CrossrefPubMedGoogle Scholar
  • 103 Wespes E, Eardley I, Giuliano F. , et al. Male sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU. Update 2013
    PubMedGoogle Scholar
  • 104 Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med 2013; 10 (Suppl. 01) 102-111
    CrossrefPubMedGoogle Scholar
  • 105 Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001; 28 (02) 309-319
    CrossrefPubMedGoogle Scholar
  • 106 Isidori AM, Giannetta E, Gianfrilli D. , et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63 (04) 381-394
    CrossrefPubMedGoogle Scholar
  • 107 Kostis JB, Jackson G, Rosen R. , et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (02) 313-321
    CrossrefPubMedGoogle Scholar
  • 108 Althof SE, Rosen R, Rubio-Aurioles E. , et al. Psychologic and interpersonal aspects and their management. In: Porst H, Buvat J. (eds). Standard Practice in Sexual Medicine. Malden: Blackwell Publishing; 2006: 18-30
    CrossrefGoogle Scholar
  • 109 Yuan J, Zhang R, Yang Z. , et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63 (05) 902-912
    CrossrefPubMedGoogle Scholar
  • 110 Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53 (Suppl. 01) 61S-65S
    CrossrefPubMedGoogle Scholar
  • 111 Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (2, Suppl): 12-27
    PubMedGoogle Scholar
  • 112 Hellstrom WJ, Gittelman M, Karlin G. , et al; Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61 (04) (Suppl. 01) 8-14
    PubMedGoogle Scholar
  • 113 Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16 (06) 470-478 (level I)
    CrossrefPubMedGoogle Scholar
  • 114 Stief C, Porst H, Sáenz De Tejada I, Ulbrich E, Beneke M. ; Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58 (03) 230-239
    CrossrefPubMedGoogle Scholar
  • 115 Interaction with Alcohol. Levitra interview form. 7th ed. 2007
    Google Scholar
  • 116 Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 01) S57-S64
    CrossrefPubMedGoogle Scholar
  • 117 Brock GB, McMahon CG, Chen KK. , et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Pt 1): 1332-1336
    CrossrefPubMedGoogle Scholar
  • 118 Kloner RA, Jackson G, Hutter AM. , et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97 (12) 1778-1784
    CrossrefPubMedGoogle Scholar
  • 119 Chen Y, Cui S, Lin H. , et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 2012; 24 (06) 217-220
    CrossrefPubMedGoogle Scholar
  • 120 Safety Interaction with Alcohol. Ciallis interview form. 2007
    PubMedGoogle Scholar
  • 121 Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170 (6 Pt 1): 2356-2358
    CrossrefPubMedGoogle Scholar
  • 122 Barada J. Salvage of ‘sildenafil (Viagra) failures’ benefits of patient and retreatment with sildenafil. Int J Impot Res 2001; 13 (Suppl. 04) S49-S50
    CrossrefPubMedGoogle Scholar
  • 123 Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006; 18 (02) 146-149
    CrossrefPubMedGoogle Scholar
  • 124 Wang R, Burnett AL, Heller WH. , et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9 (08) 2122-2129
    CrossrefPubMedGoogle Scholar
  • 125 Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother 2013; 47 (10) 1312-1320
    CrossrefPubMedGoogle Scholar
  • 126 Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin 2014; 30 (08) 1565-1571
    CrossrefPubMedGoogle Scholar
  • 127 Goldstein I, McCullough AR, Jones LA. , et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9 (04) 1122-1133
    CrossrefPubMedGoogle Scholar
  • 128 Sur RL, Kane CJ. ; RL. Sildenafil citrate-associated priapism. Urology 2000; 55 (06) 950
    CrossrefPubMedGoogle Scholar
  • 129 King SH, Hallock M, Strote J, Wessells H. Tadalafil-associated priapism. Urology 2005; 66 (02) 432
    PubMedGoogle Scholar
  • 130 Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994; 14 (01) 38-44
    PubMedGoogle Scholar
  • 131 McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2 (03) 415-425 , discussion 425–427
    CrossrefPubMedGoogle Scholar
  • 132 Porst H, Giuliano F, Glina S. , et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50 (02) 351-359
    CrossrefPubMedGoogle Scholar
  • 133 Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19 (01) 95-103
    CrossrefPubMedGoogle Scholar
  • 134 Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008; 54 (01) 204-210
    CrossrefPubMedGoogle Scholar
  • 135 Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47 (02) 214-220 , discussion 220–222
    CrossrefPubMedGoogle Scholar
  • 136 Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19 (02) 200-207
    CrossrefPubMedGoogle Scholar
  • 137 Aversa A, Vitale C, Volterrani M. , et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25 (01) 37-44
    CrossrefPubMedGoogle Scholar
  • 138 Porst H, Gacci M, Büttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65 (02) 455-464
    CrossrefPubMedGoogle Scholar
  • 139 Linet OI, Ogrinc FG. ; The Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334 (14) 873-877
    CrossrefPubMedGoogle Scholar
  • 140 Padma-Nathan H, Hellstrom WJ, Kaiser FE. , et al; Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 141 Garrido Abad P, Sinués Ojas B, Martínez Blázquez L, Conde Caturla P, Fernández Arjona M. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. Actas Urol Esp 2015; 39 (10) 635-640
    CrossrefPubMedGoogle Scholar
  • 142 Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15 (01) 78-82
    CrossrefPubMedGoogle Scholar
  • 143 Sun L, Peng FL, Yu ZL, Liu CL, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol 2014; 21 (12) 1263-1267
    CrossrefPubMedGoogle Scholar
  • 144 Engel JD. Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol 2011; 18 (03) 5721-5725
    PubMedGoogle Scholar
  • 145 Nason GJ, McNamara F, Twyford M. , et al. Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. Int J Impot Res 2016; 28 (06) 205-208
    CrossrefPubMedGoogle Scholar
  • 146 Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med 2013; 10 (01) 195-203
    CrossrefPubMedGoogle Scholar
  • 147 Alemozaffar M, Regan MM, Cooperberg MR. , et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306 (11) 1205-1214
    CrossrefPubMedGoogle Scholar
  • 148 Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293 (21) 2648-2653
    CrossrefPubMedGoogle Scholar
  • 149 Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med 2009; 6 (09) 2538-2546
    CrossrefPubMedGoogle Scholar
  • 150 Walsh PC. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J Urol 2007; 177 (05) 1632-1635
    CrossrefPubMedGoogle Scholar
  • 151 Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 2009; 6 (08) 415-427
    PubMedGoogle Scholar
  • 152 Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164 (06) 1929-1934
    CrossrefPubMedGoogle Scholar
  • 153 Tal R, Teloken P, Mulhall JP. Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members. J Sex Med 2011; 8 (08) 2370-2376
    CrossrefPubMedGoogle Scholar
  • 154 Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55 (02) 334-347
    CrossrefPubMedGoogle Scholar
  • 155 Padma-Nathan H, McCullough A, Giuliano F. , et al. Postoperative nightly administration of sildenafil citrate significantly improved the return of normal spontaneous erectile function after bilateral nerve-sparing radical pros- tatectomy. J Urol 2003; 4: 375
    PubMedGoogle Scholar
  • 156 Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2 (04) 532-540 , discussion 540–542
    CrossrefPubMedGoogle Scholar
  • 157 Gallo L, Perdonã S, Autorino R. , et al. Recovery of erection after pelvic urologic surgery: our experience. Int J Impot Res 2005; 17 (06) 484-493
    CrossrefPubMedGoogle Scholar
  • 158 Brock G, Nehra A, Lipshultz LI. , et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170 (4 Pt 1): 1278-1283
    CrossrefPubMedGoogle Scholar
  • 159 Montorsi F, Brock G, Lee J. , et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54 (04) 924-931
    CrossrefPubMedGoogle Scholar
  • 160 Kovanecz I, Rambhatla A, Ferrini MG. , et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008; 101 (02) 203-210
    PubMedGoogle Scholar
  • 161 Vignozzi L, Filippi S, Morelli A. , et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006; 3 (03) 419-431
    CrossrefPubMedGoogle Scholar
  • 162 Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol 2006; 16 (03) 186-195
    CrossrefPubMedGoogle Scholar
  • 163 Montorsi F, Guazzoni G, Strambi LF. , et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158 (04) 1408-1410
    CrossrefPubMedGoogle Scholar
  • 164 Raina R, Agarwal A, Ausmundson S. , et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18 (01) 77-81
    CrossrefPubMedGoogle Scholar
  • 165 Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2013; 111 (04) 658-665
    CrossrefPubMedGoogle Scholar
  • 166 Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharma- cological penile rehabilitation: Practice patterns among ISSM practitioners. J Sex Med 2009; 6: 2032-2038
    CrossrefPubMedGoogle Scholar
  • 167 Dall'era JE, Mills JN, Koul HK, Meacham RB. Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking?. Rev Urol 2006; 8 (04) 209-215
    PubMedGoogle Scholar
  • 168 Salonia A, Burnett AL, Graefen M. , et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012; 62 (02) 273-286
    CrossrefPubMedGoogle Scholar
  • 169 Babaei AR, Safarinejad MR, Kolahi AA. Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications. Urol J 2009; 6 (01) 1-7
    PubMedGoogle Scholar
  • 170 Henry GD, Brinkman MJ, Mead SF. , et al. A survey of patients with inflatable penile prostheses: assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med 2012; 9 (06) 1715-1721
    CrossrefPubMedGoogle Scholar
  • 171 Scherzer ND, Dick B, Gabrielson AT, Alzweri LM, Hellstrom WJG. Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sex Med Rev 2018
    PubMedGoogle Scholar
  • 172 Bettocchi C, Palumbo F, Spilotros M. , et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010; 7 (1 Pt 1): 304-309
    CrossrefPubMedGoogle Scholar
  • 173 Carvalheira A, Santana R, Pereira NM. Why are men satisfied or dissatisfied with penile implants? A mixed method study on satisfaction with penile prosthesis implantation. J Sex Med 2015; 12 (12) 2474-2480
    CrossrefPubMedGoogle Scholar
  • 174 Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am 2001; 28 (02) 355-361 , x
    CrossrefPubMedGoogle Scholar
  • 175 Wang R, Howard GE, Hoang A, Yuan JH, Lin HC, Dai YT. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl 2009; 11 (04) 411-415
    CrossrefPubMedGoogle Scholar
  • 176 Levine LA, Becher EF, Bella AJ. , et al. Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine. J Sex Med 2016; 13 (04) 489-518
    CrossrefPubMedGoogle Scholar
  • 177 Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J 2017; 93 (1105): 679-685
    CrossrefPubMedGoogle Scholar
  • 178 Khera M, Albersen M, Mulhall JP. Mesenchymal stem cell therapy for the treatment of erectile dysfunction. J Sex Med 2015; 12 (05) 1105-1106
    CrossrefPubMedGoogle Scholar
  • 179 Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol 2016; 50 (02) 123-127
    PubMedGoogle Scholar
  • 180 Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwave treatment of erectile dysfunction. Ther Adv Urol 2013; 5 (02) 95-99
    CrossrefPubMedGoogle Scholar
  • 181 Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 2012; 9 (01) 259-264
    CrossrefPubMedGoogle Scholar
  • 182 Sexual Medicine Society. POSITION STATEMENT: ED Restorative (Regenerative) Therapies (shock waves, autologous platelet rich plasma, and stem cells). Available at: http://email.mg.smsna.org/c/eJwNjsFuhCAURb9Gl0SQUViwmEW7a9OMTbfkIU8kHcXwsGb-viQ3N-euzvXGOwm8jWYZe6dUp2_D7PueK-GFGpXUXmktsXON7EJiVKCcdDxPYjuWdjWoRtTzwgWgk7cFB1CAcuBSDJ0ehWifZi3laPp7I95rrutitNEOLOVQ9w-vFTcISBWmj-nzbr8SxRLTbqdqww33Yh9v9oFUUoYS_9B-r5jhiEjs8EubjcvJY47zLwsZQ8qv-naDV2Loz38FZUqA
    PubMedGoogle Scholar
  • 183 Hackett G, Kirby M, Wylie K. , et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in Men—2017. J Sex Med 2018; 15 (04) 430-457
    CrossrefPubMedGoogle Scholar
  • 184 Thirumavalavan N, Hoover CRV, Gross MS. Surgeons Corner: Cavernoscopy for Rear Tip Extender Removal. J Sex Med 2018; 15 (08) 1195-1197
    CrossrefPubMedGoogle Scholar
  • 185 Kim BH, Lim HS, Chung JY. , et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008; 65 (06) 848-854
    CrossrefPubMedGoogle Scholar
  • 186 Glina S, Toscano I, Gomatzky C. , et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009; 6 (02) 553-557
    CrossrefPubMedGoogle Scholar
  • 187 Moon KH, Ko YH, Kim SW. , et al. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial. J Sex Med 2015; 12 (05) 1194-1201
    CrossrefPubMedGoogle Scholar
  • 188 Hatzimouratidis K, Salonia A, Adaikan G. , et al. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2016; 13 (04) 465-488
    CrossrefPubMedGoogle Scholar